Register | Login
Intellectual Property Today
RFC Express - Document Management System
Now Available!
2010 Top Trademark Firms
2010 Top Patent Firms
Current Issue
Cotsis CAD

Advertising Opportunities

Click Here

Email A Friend Back to Intellectual Property News

EPO Rules European Patent for XP13512 Is Valid

Thursday, April 15, 2010

Santa Clara, CA -- XenoPort, Inc. (Nasdaq: XNPT) announced today that the European Patent Office (EPO) Opposition Division ruled that the European patent for the composition of matter of XP13512 (European Patent No. 1 404 324) is valid. This favorable decision means that XenoPort retains composition-of-matter protection on multiple forms of XP13512 molecules, and its patent continues to be valid in Austria, Belgium, Switzerland and Liechtenstein, Cyprus, Germany, Denmark, Spain, Finland, France, UK, Greece, Ireland, Italy, Luxembourg, Monaco, The Netherlands, Portugal, Sweden and Turkey until June 2022.

XP13512 is a new chemical entity that is being developed for restless legs syndrome, neuropathic pain and migraine prophylaxis. This investigational compound, also known as Horizant™ (gabapentin enacarbil) in the United States, is not presently marketed anywhere in the world.

About XenoPort

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is collaborating with Astellas Pharma Inc. and GlaxoSmithKline to develop and commercialize XP13512. XenoPort’s product candidates are being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity and Parkinson’s disease. To learn more about XenoPort, please visit the web site at

XenoPort is a registered trademark of XenoPort, Inc.

Horizant is a trademark of GlaxoSmithKline.

Back to Intellectual Property News
Looking for...

  © Copyright 2010 Intellectual Property Today — Designed By
Download Adobe Reader for free